Insulin-dependent diabetes mellitus in adults (ICD, type 2), if other measures, such as strict adherence to a diabetic diet, reducing excess body weight, and sufficient physical activity did not lead to satisfactory control of blood glucose levels.
Maninil composition active substance: glibenclamide;
1 tablet contains glibenclamide 5 mg;
Excipients: lactose monohydrate, potato starch, gelatin, magnesium stearate, talc, ponso 4R (E 124).
It is a sugar and cholesterol lowering agent. Specifically stimulates cells such as the beta islet apparatus, increasing the production of insulin by the pancreas. Its activity is manifested with the preserved insulin-synthetic function of the gland. The drug restores the normal sensitivity of beta cells to blood sugar levels. It potentiates the effect of insulin (both endogenous and exogenous) by increasing the number of receptors. Restores post-receptor signal transduction, improves insulin-receptor interaction.
Maninil is used in type II diabetes mellitus in conditions of impossibility to compensate for hyperglycemia by physical activity, weight loss, and diet.
- with hypersensitivity to sulfa drugs, thiazide diuretics;
- with diabetic precomatose / coma;
- with ketoacidosis;
- with extensive burns;
- during surgical interventions, injuries;
- with intestinal obstruction;
- with paresis of the stomach;
- in conditions accompanied by impaired absorption of food;
- with type I diabetes mellitus;
- with the development of hypoglycemia;
- with hypo / hyperthyroidism;
- with liver / kidney dysfunction;
- with leukopenia;
- during pregnancy / lactation.
The safety and efficacy of Maninil in children have not been established. Therefore, this drug should not be used to treat children.
Application during pregnancy and lactation
The category of action on the fetus is C according to the FDA (studies on animals have shown a negative effect on the fetus, however, proper studies have not been carried out in women).
Breastfeeding is stopped for the duration of treatment.
Method of administration and dosage
Apply Maninil orally in one or two doses (30 minutes before meals).
The standard starting dose is 1.75-3.5 mg / day. If necessary, it is increased to 10-15 mg / day. The maximum is 20 mg / day.
After normalization of glycemia, 1.75-5 mg / day is used.
Overdose symptoms: hypoglycemia (manifested by a feeling of hunger, anxiety, severe weakness, headache, dizziness, palpitations, sweating, muscle tremors, speech and vision disorders, cerebral edema, impaired consciousness, the development of hypoglycemic coma).
Therapeutic measures: in mild cases – taking sugar (sweet tea, juice, honey, syrup); in severe cases, intravenous administration of 40% glucose solution, continuous infusion of 5–10% dextrose solution, intramuscular administration of glucagon (1–2 mg), oral administration of 200 mg diazoxide every 4 hours or 30 mg intravenously for 30 minutes; with cerebral edema – the introduction of mannitol, dexamethasone. It is necessary to monitor glycemia every 15 minutes, creatinine, pH, urea nitrogen, electrolytes in the blood.
- Hematological disorders: thrombocytopenia, erythrocytopenia, granulocytopenia, pancytopenia, leukocytopenia, eosinophilia, agranulocytosis, hemolytic or hypoplastic anemia.
- Neurological disorders: headache, change in taste, dizziness.
- Metabolic disorders: hypoglycemia, late cutaneous porphyria, proteinuria.
- Gastrointestinal disorders: cholestasis, liver dysfunction, dyspepsia.
- Allergic reactions: photosensitivity, rashes (erythema, exfoliative dermatitis).
- Others: polyuria, fever, arthralgia, weight gain.
Storage conditions and periods
Store Maninil in its original packaging at temperatures up to 25 ° C.
It is good for three years after production.